Every Form 4 that Fennec Pharmaceuticals Inc. (FENC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow FENC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FENC filings page.
FENNEC PHARMACEUTICALS INC. Chief Strategy Officer Christiana Marie Cioffi exercised stock options to acquire 4,700 common shares at an exercise price of $4.23 per share. Following the transaction, she holds 145,300 common shares directly, indicating an exercise-and-hold transaction with no reported share sales.
Fennec Pharmaceuticals Inc. reported that its Chief Financial Officer, Robert Andrade, acquired 1,191 common shares as a grant or award at a price of $0.00 per share. A footnote explains these shares were released from restrictions on awards originally granted on 3/31/2023 and 5/16/2024. Following this transaction, Andrade directly owns 243,584 common shares.
FENNEC PHARMACEUTICALS INC. director Rosty Raykov reported multiple equity transactions. On March 2, 2026, he exercised 15,598 stock options at $2.45 per share, receiving the same number of common shares under a 10b5-1 plan adopted on September 19, 2025. He then sold 10,079 common shares at $8.36 per share to cover tax obligations linked to the option exercise. On February 28, 2026, he also acquired 5,208 common shares at no cost as previously awarded shares were released from restrictions. After these transactions, his direct common share holdings were 103,996 shares.
FENNEC PHARMACEUTICALS INC. Chief Executive Officer Jeffrey S. Hackman acquired common shares through an equity award vesting. On settlement of performance share units that vested on February 18, 2026, he received 13,710 common shares at no stated exercise price. Following this non-cash derivative exercise, his direct ownership increased to 28,710 common shares.
FENNEC PHARMACEUTICALS INC. chief financial officer Robert Andrade reported equity award activity involving both stock options and performance share units. On February 18, 2026, he exercised stock options for 2,450 shares at $4.08 per share, resulting in 215,108 common shares held directly after that transaction. He also acquired 27,285 additional common shares at no exercise price through the settlement of PSUs that vested on the same date, bringing his directly held common shares to 242,393. Following these transactions, his directly held stock options totaled 814,117.
Fennec Pharmaceuticals director Rosty Raykov reported insider transactions involving stock options and common shares. On February 2, 2026, he exercised 15,598 stock options at an exercise price of $2.45 per option under a Rule 10b5-1 trading plan adopted on September 19, 2025, receiving the same number of common shares.
On the same date, he sold 10,349 common shares at $7.76 per share to satisfy tax obligations related to the option exercise. After these transactions, he directly owned 98,477 common shares and 1,602,988 stock options in Fennec Pharmaceuticals.
Fennec Pharmaceuticals director Rosty Raykov reported a routine equity change as 5,208 common shares were acquired on January 31, 2026 at a price of $0 per share. These shares were released from restrictions tied to awards originally granted on March 31, 2023 and May 16, 2024.
Following this release of previously awarded stock, Raykov directly beneficially owns 93,228 common shares of Fennec Pharmaceuticals. The filing reflects a non-cash change in ownership from restricted to freely releasable shares rather than an open-market purchase or sale.
Fennec Pharmaceuticals chief financial officer Robert Andrade reported an equity change in the company’s common shares. On January 31, 2026, he acquired 1,558 common shares at a price of $0 per share through the release of restrictions on previously awarded shares.
These shares were released from restriction from awards originally granted on March 31, 2023 and May 16, 2024. Following this vesting event, Andrade directly holds a total of 212,658 common shares of Fennec Pharmaceuticals.
Fennec Pharmaceuticals Inc. chief financial officer exercises stock options for 10,000 shares. On January 23, 2026, CFO Robert Andrade exercised stock options with a strike price of $2.45 per share, acquiring 10,000 common shares of Fennec Pharmaceuticals Inc. following an option contract that was scheduled to expire on July 5, 2026.
After this transaction, Andrade directly held 211,100 common shares of Fennec and still held 816,567 stock options with an exercise price of $2.45, according to the filing.
Fennec Pharmaceuticals Inc. reported an insider transaction by its Chief Financial Officer, Robert Andrade. On 01/15/2026, he exercised 10,000 stock options with an exercise price of $2.45 per share, acquiring 10,000 common shares.
Following the transaction, Andrade directly beneficially owned 201,100 common shares and held 826,567 stock options that remained outstanding. The shares were acquired through the exercise of an option contract with a strike price of $2.45 and an expiration date of July 5, 2026.
Fennec Pharmaceuticals chief financial officer Robert Andrade reported exercising stock options and acquiring common shares of the company. On January 7, 2026, he exercised 14,184 stock options at an exercise price of $2.45 per share, which resulted in acquiring 14,184 common shares. After this transaction, he beneficially owned 191,100 common shares directly and held 836,567 stock options directly.
Fennec Pharmaceuticals director reports vested share award
A director of Fennec Pharmaceuticals Inc. reported the acquisition of 5,208 common shares of the company on 12/01/2025. The filing shows these shares were released from restrictions tied to awards originally granted on 3/31/2023 and 5/16/2024, so no purchase price was paid and the transaction is recorded at $0 per share.
Following this vesting event, the director now beneficially owns 87,526 common shares, held directly. The transaction was reported on a Form 4 filed for a single reporting person in the capacity of director of Fennec Pharmaceuticals Inc. (FENC).
Fennec Pharmaceuticals (FENC) reported an insider share sale by a major holder. On 11/18/2025, an affiliated fund of Southpoint, for which John S. Clark II and related Southpoint entities serve as general partners and managers, sold 19,341 shares of Fennec common stock in open-market transactions. The weighted average sale price was $8.7921 per share across trades executed between $8.75 and $8.845 per share. After this sale, the reporting persons collectively report 3,744,741 shares of Fennec common stock beneficially owned indirectly, while each disclaims beneficial ownership beyond their pecuniary interest.
Fennec Pharmaceuticals Inc. (FENC) received a Form 4 reporting sales of its common stock by a director and more than 10% owner group affiliated with Southpoint. On 11/14/2025, the reporting persons sold 160,100 shares of common stock at a weighted average price of $7.9977 per share. On 11/17/2025, they sold an additional 85,918 shares at a weighted average price of $8.7897 per share. Following these transactions, the group reports indirect beneficial ownership of 3,764,082 Fennec common shares through Southpoint Master Fund, LP and its related investment entities. The filing notes that each reporting person disclaims beneficial ownership beyond its or his pecuniary interest.
Fennec Pharmaceuticals (FENC) reported an insider transaction on a Form 4. Director Rosty Raykov sold 10,000 common shares on 11/05/2025 at $8.10 per share in an open-market sale. Following the transaction, he beneficially owns 82,318 shares, held directly.
The sale was made pursuant to a Rule 10b5-1 trading plan dated August 23, 2024, indicating pre‑arranged trading parameters.
Fennec Pharmaceuticals (FENC) reported an insider equity change. Director Rosty Raykov acquired 5,208 common shares on 10/31/2025 at $0, reflecting the release of restricted shares previously awarded on 3/31/2023 and 5/16/2024. Following this transaction, Raykov beneficially owns 92,318 shares, held directly.
The filing lists no derivative transactions in Table II.
Fennec Pharmaceuticals (FENC) Form 4: Chief Financial Officer Robert Andrade reported acquiring 2,430 common shares at $0 on 10/31/2025. The filing states these shares were released from restriction related to awards granted on 3/31/2023 and 5/16/2024. Following the transaction, Andrade beneficially owns 173,104 shares, held directly.
Fennec Pharmaceuticals (FENC) reported an insider transaction by a director on 10/10/2025. The director exercised 4,062 options at a $1.23 exercise price under a 10b5-1 plan adopted on May 19, 2025, acquiring the same number of common shares. To cover taxes from the exercise, the insider sold 1,775 shares at $9.24. Following these transactions, the insider beneficially owned 57,079 common shares directly and held 174,344 derivative securities (options) after the reported activity.
Fennec Pharmaceuticals (FENC) insiders filed a Form 4 reporting multiple open-market sales of common stock across 10/07/2025 to 10/09/2025
Reporting entities tied to Southpoint (Southpoint Capital Advisors LP/LLC, Southpoint GP entities and John S. Clark II) sold a total of 67,114 shares in three tranches at weighted-average prices of approximately $9.5871, $9.4732, and $9.3461. Reported beneficial ownership after each trade was 4,050,314, 4,030,709, and 4,010,100 shares respectively. The filing explains that the shares are held directly by Southpoint Master Fund, LP and that the reporting persons disclaim beneficial ownership except for pecuniary interest.
Insider exercised options to buy 4,609 common shares at $2.45, increasing direct beneficial ownership to 87,110 shares. The transaction was executed on 10/08/2025 via exercise of stock options that carry a $2.45 strike and expire on 07/05/2026. After the exercise the reporting person holds 4,609 underlying options shown as exercised and 1,634,184 remaining outstanding options in the same class per the filing table. The form is a Section 16 filing by a director, showing a routine option exercise rather than a market sale or open-market purchase.